Johnson & Johnson JNJ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Preview — Barron's
-
Becton Dickinson to Invest $19 Billion in U.S. in Exchange for Tariff Relief — Update
-
J&J Says In-Development Blood-Cancer Treatment Shows Promise
-
Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint
-
Johnson & Johnson Gets FDA Approval for Imaavy to Treat Warm Autoimmune Hemolytic Anemia
-
Moderna's cancer-vaccine breakthrough drives broad biopharma stock rally
-
Johnson & Johnson on Track for Record High Close — Data Talk
-
Johnson & Johnson On Pace for Record High Close — Data Talk
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 2.41B
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 23.26
- Price/Sales
- 6.29
- Dividend Yield (Trailing)
- 2.09%
- Dividend Yield (Forward)
- 2.12%
- Dividend Payment Schedule
- Mar, Jun, Sep, Dec
- Total Yield
- 3.37%
Company Profile
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 140,800
- Website
- https://www.jnj.com
Competitors
Valuation
|
Metric
|
JNJ
|
NVS
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 23.26 | 13.83 | 45.36 |
Price/Book Value | 7.16 | 6.58 | 8.57 |
Price/Sales | 6.29 | 4.89 | 5.43 |
Price/Cash Flow | 21.56 | 14.43 | 16.30 |
Price/Earnings
JNJ
NVS
MRK
Financial Strength
|
Metric
|
JNJ
|
NVS
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.73 | 0.55 | 0.71 |
Current Ratio | 1.09 | 0.86 | 1.32 |
Interest Coverage | 25.00 | 11.90 | 4.28 |
Quick Ratio
JNJ
NVS
MRK
Profitability
|
Metric
|
JNJ
|
NVS
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 13.42% | 14.74% | 6.27% |
Return on Equity (Normalized) | 32.69% | 39.06% | 16.68% |
Return on Invested Capital (Normalized) | 20.33% | 21.25% | 9.82% |
Return on Assets
JNJ
NVS
MRK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|#^h&?Y!! | LOCK|%d | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|CpLQr^h | LOCK|K? | $630B | |||
| AbbVie Inc
ABBV
| LOCK|?lgC@# | LOCK|hlV | $489B | |||
| Merck & Co Inc
MRK
| LOCK|mG&Xtyf | LOCK|T& | $359B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|P#kBCj# | LOCK|>Kx | $344B | |||
| Novartis AG ADR
NVS
| LOCK|C%%nz@V | LOCK|#@ | $272B | |||
| AstraZeneca PLC
AZN
| LOCK|G!Y?WF<y | LOCK|v$ | $244B | |||
| Amgen Inc
AMGN
| LOCK|%$$zMvTM | LOCK|P^ | $224B | |||
| Gilead Sciences Inc
GILD
| LOCK|k@&x<V | LOCK|NFj | $187B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|%<<VSMm | LOCK|b% | $169B |
United States